Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 162

Results For "SEC"

3011 News Found

Lonza collaborates with Vertex on cell, gene technologies manufacturing
News | June 28, 2023

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)


Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies
News | June 27, 2023

Biotium introduces novel antibody labeling Kits for efficient labeling of IgM antibodies

Mix-n-Stain CF Dye IgM Antibody Labeling Kits address longstanding challenges for labeling IgM antibodies by offering efficient and convenient conjugation with bright CF Dyes


Venus Remedies receives approval to market meropenm in Spain
News | June 23, 2023

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries


LVPEI raises awareness on antimicrobial resistance among medical students
News | June 23, 2023

LVPEI raises awareness on antimicrobial resistance among medical students

Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety


Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states
News | June 22, 2023

Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states

Effective disaster response and management is a collaborative work


Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
News | June 21, 2023

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency


Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
Drug Approval | June 20, 2023

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable